Luc Mouthon

List of Publications by Citations

Source: https://exaly.com/author-pdf/7103481/luc-mouthon-publications-by-citations.pdf

Version: 2024-04-20

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

2,395 27 48 g-index

52 2,966 4.9 4.29 ext. papers ext. citations avg, IF L-index

#	Paper	IF	Citations
47	Inhibition of maturation and function of dendritic cells by intravenous immunoglobulin. <i>Blood</i> , 2003 , 101, 758-65	2.2	252
46	Mapping and predicting mortality from systemic sclerosis. <i>Annals of the Rheumatic Diseases</i> , 2017 , 76, 1897-1905	2.4	230
45	Assessing disability and quality of life in systemic sclerosis: construct validities of the Cochin Hand Function Scale, Health Assessment Questionnaire (HAQ), Systemic Sclerosis HAQ, and Medical Outcomes Study 36-Item Short Form Health Survey. <i>Arthritis and Rheumatism</i> , 2007 , 57, 94-102		147
44	The three-year incidence of pulmonary arterial hypertension associated with systemic sclerosis in a multicenter nationwide longitudinal study in France. <i>Arthritis and Rheumatism</i> , 2009 , 60, 1831-9		145
43	Selective oxidation of DNA topoisomerase 1 induces systemic sclerosis in the mouse. <i>Journal of Immunology</i> , 2009 , 182, 5855-64	5.3	137
42	Scleroderma renal crisis: a retrospective multicentre study on 91 patients and 427 controls. <i>Rheumatology</i> , 2012 , 51, 460-7	3.9	105
41	Intravenous immunoglobulin therapy for pure red cell aplasia related to human parvovirus b19 infection: a retrospective study of 10 patients and review of the literature. <i>Clinical Infectious Diseases</i> , 2013 , 56, 968-77	11.6	94
40	Pathogenesis of giant cell arteritis: More than just an inflammatory condition?. <i>Autoimmunity Reviews</i> , 2010 , 9, 635-45	13.6	88
39	The Scleroderma Patient-centered Intervention Network (SPIN) Cohort: protocol for a cohort multiple randomised controlled trial (cmRCT) design to support trials of psychosocial and rehabilitation interventions in a rare disease context. <i>BMJ Open</i> , 2013 , 3,	3	82
38	Therapeutic strategy combining intravenous cyclophosphamide followed by oral azathioprine to treat worsening interstitial lung disease associated with systemic sclerosis: a retrospective multicenter open-label study. <i>Journal of Rheumatology</i> , 2008 , 35, 1064-72	4.1	80
37	Efficacy of sildenafil on ischaemic digital ulcer healing in systemic sclerosis: the placebo-controlled SEDUCE study. <i>Annals of the Rheumatic Diseases</i> , 2016 , 75, 1009-15	2.4	76
36	Treatment outcome in early diffuse cutaneous systemic sclerosis: the European Scleroderma Observational Study (ESOS). <i>Annals of the Rheumatic Diseases</i> , 2017 , 76, 1207-1218	2.4	71
35	Scleroderma renal crisis. <i>Journal of Rheumatology</i> , 2014 , 41, 1040-8	4.1	65
34	Mechanisms of action of intravenous immunoglobulin. <i>Transfusion and Apheresis Science</i> , 2017 , 56, 45-4	192.4	58
33	Intravenous immunoglobulin induces proliferation and immunoglobulin synthesis from B cells of patients with common variable immunodeficiency: a mechanism underlying the beneficial effect of IVIg in primary immunodeficiencies. <i>Journal of Autoimmunity</i> , 2011 , 36, 9-15	15.5	55
32	Systemic sclerosis-associated myopathy. Annals of the New York Academy of Sciences, 2007, 1108, 268-8	32 6.5	53
31	Recommendations for the care of oral involvement in patients with systemic sclerosis. <i>Arthritis Care and Research</i> , 2011 , 63, 1126-33	4.7	48

30	Intravenous immunoglobulin expands regulatory T cells in autoimmune rheumatic disease. <i>Journal of Rheumatology</i> , 2012 , 39, 450-1	4.1	43
29	Pathophysiology of systemic sclerosis: state of the art in 2014. <i>Presse Medicale</i> , 2014 , 43, e267-78	2.2	41
28	Endothelin-1 expression in scleroderma renal crisis. <i>Human Pathology</i> , 2011 , 42, 95-102	3.7	40
27	Personalized Physical Therapy Versus Usual Care for Patients With Systemic Sclerosis: A Randomized Controlled Trial. <i>Arthritis Care and Research</i> , 2017 , 69, 1050-1059	4.7	38
26	Scleroderma Peripheral B Lymphocytes Secrete Interleukin-6 and Transforming Growth Factor I and Activate Fibroblasts. <i>Arthritis and Rheumatology</i> , 2017 , 69, 1078-1089	9.5	36
25	Disability, fatigue, pain and their associates in early diffuse cutaneous systemic sclerosis: the European Scleroderma Observational Study. <i>Rheumatology</i> , 2018 , 57, 370-381	3.9	36
24	Performance of the Patient-Reported Outcomes Measurement Information System-29 in scleroderma: a Scleroderma Patient-centered Intervention Network Cohort Study. <i>Rheumatology</i> , 2017 , 56, 1302-1311	3.9	34
23	Lung and heart-lung transplantation for systemic sclerosis patients. A monocentric experience of 13 patients, review of the literature and position paper of a multidisciplinary Working Group. <i>Presse Medicale</i> , 2014 , 43, e345-63	2.2	34
22	IgG from patients with pulmonary arterial hypertension and/or systemic sclerosis binds to vascular smooth muscle cells and induces cell contraction. <i>Annals of the Rheumatic Diseases</i> , 2012 , 71, 596-605	2.4	32
21	Intravenous immunoglobulin-induced IL-33 is insufficient to mediate basophil expansion in autoimmune patients. <i>Scientific Reports</i> , 2014 , 4, 5672	4.9	30
20	Proteomes of umbilical vein and microvascular endothelial cells reflect distinct biological properties and influence immune recognition. <i>Proteomics</i> , 2012 , 12, 2547-55	4.8	24
19	Identification of target antigens of anti-endothelial cell antibodies in patients with anti-neutrophil cytoplasmic antibody-associated vasculitides: a proteomic approach. <i>Clinical Immunology</i> , 2014 , 153, 123-35	9	23
18	Validation of the Self-Efficacy for Managing Chronic Disease Scale: A Scleroderma Patient-Centered Intervention Network Cohort Study. <i>Arthritis Care and Research</i> , 2016 , 68, 1195-200	4.7	23
17	mTOR pathway is activated in endothelial cells from patients with Takayasu arteritis and is modulated by serum immunoglobulin G. <i>Rheumatology</i> , 2018 , 57, 1011-1020	3.9	22
16	Levamisole-induced vasculopathy: A systematic review. <i>Seminars in Arthritis and Rheumatism</i> , 2019 , 48, 921-926	5.3	21
15	Generation of a Core Set of Items to Develop Classification Criteria for Scleroderma Renal Crisis Using Consensus Methodology. <i>Arthritis and Rheumatology</i> , 2019 , 71, 964-971	9.5	21
14	Proteomic analysis of vascular smooth muscle cells in physiological condition and in pulmonary arterial hypertension: Toward contractile versus synthetic phenotypes. <i>Proteomics</i> , 2016 , 16, 2637-2649	4.8	18
13	Molecular analysis of vascular smooth muscle cells from patients with giant cell arteritis: Targeting endothelin-1 receptor to control proliferation. <i>Autoimmunity Reviews</i> , 2017 , 16, 398-406	13.6	17

12	Corticosteroid-sparing benefit of intravenous immunoglobulin in systemic sclerosis-associated myopathy: A comparative study in 52 patients. <i>Autoimmunity Reviews</i> , 2020 , 19, 102431	13.6	13
11	Contribution of antiferritin antibodies to diagnosis of giant cell arteritis. <i>Annals of the Rheumatic Diseases</i> , 2013 , 72, 1269-70	2.4	12
10	Mycophenolate mofetil following cyclophosphamide in worsening systemic sclerosis-associated interstitial lung disease. <i>Journal of Scleroderma and Related Disorders</i> , 2016 , 1, 234-240	2.3	11
9	Utilization of intravenous or subcutaneous immunoglobulins in secondary immune deficiency (ULTIMATE): A retrospective multicenter study. <i>Clinical Immunology</i> , 2020 , 215, 108419	9	7
8	Extra-haematological manifestations related to human parvovirus B19 infection: retrospective study in 25 adults. <i>BMC Infectious Diseases</i> , 2018 , 18, 302	4	6
7	Proteomic Analysis of Human Scleroderma Fibroblasts Response to Transforming Growth Factor-Il <i>Proteomics - Clinical Applications</i> , 2019 , 13, e1800069	3.1	3
6	The Scleroderma Patient-Centered Intervention Network Self-Management Program: Protocol for a Randomized Feasibility Trial. <i>JMIR Research Protocols</i> , 2020 , 9, e16799	2	3
5	French recommendations for the management of systemic sclerosis. <i>Orphanet Journal of Rare Diseases</i> , 2021 , 16, 322	4.2	3
4	Pathophysiology of systemic sclerosis. <i>Presse Medicale</i> , 2021 , 50, 104087	2.2	2
3	The Scleroderma Patient-centered Intervention Network Self-Management (SPIN-SELF) Program: protocol for a two-arm parallel partially nested randomized controlled feasibility trial with progression to full-scale trial. <i>Trials</i> , 2021 , 22, 856	2.8	1
2	Treatment of systemic sclerosis. <i>Presse Medicale</i> , 2021 , 50, 104088	2.2	0
1	Randomized feasibility trial of the Scleroderma Patient-centered Intervention Network Self-Management (SPIN-SELF) Program <i>Pilot and Feasibility Studies</i> , 2022 , 8, 45	1.9	0